Realizing the Potential of CDK 4/6 Inhibitor Therapy in HR+/HER2-
Metastatic Breast Cancer: Managed Care Considerations
on Recent Evidence in Real-World Practice

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of HR+/HER2-metastatic breast cancer

These are archives of live webinars held on December 13, 2021 and December 17, 2021.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from January 1, 2022 to January 1, 2024


This series is supported by an educational grant from
Pfizer

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Description:
Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. The incidence in women in the United States is 1 in 8 (about 13 percent). About 43,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Fortunately for advanced breast cancer patients with HR+/HER2- advanced breast cancer, several new agents, including CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent real-world data has been released that shows the strong efficacy and safety of these options. With this new data becoming available, it is imperative to provide medical directors, oncologists, pharmacy directors, oncology case managers and others on the interprofessional management team with this new data and best practices on the evolving treatment paradigm, with the ultimate goal of optimizing access and improving outcomes for patients who would benefit from these options.


A Closer Look at Recent Real-World and Clinical Trial Data in the Management of HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on the Evolving Role of CDK 4/6 Inhibitors

  1. Examine the unmet clinical needs in HR+/HER2- metastatic breast cancer and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Analyze recent efficacy and safety data on CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer
  3. Explore real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer
  4. Evaluate best practices for analyzing, interpreting and utilizing real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday managed care and oncology practice
  5. Compare and contrast adverse events associated with CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer in order to improve patient adherence and quality of life
       Physician, Nursing and CMCN credits valid to January 1, 2024

What Managed Care Needs to Know About Recent Real-World Evidence and Best Practices for CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: Utilizing Recent Data for Optimal Decision Making

  1. Examine the unmet economic needs in HR+/HER2- metastatic breast cancer and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Explore real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer
  3. Formulate recommendations to ensure appropriate access for first-line treatment of HR+/HER2- metastatic breast cancer with CDK 4/6 inhibitors
  4. Assess the managed care considerations of CDK 4/6 inhibitors by exploring where these agents fit into current metastatic breast cancer management paradigm
  5. Transform therapeutic advances and resource utilization data on emerging therapies in alopecia areata into informed health plan decisions and formulary discussions
       Physician, Nursing and CMCN credits valid to January 1, 2024